Oligonucleotide Synthesis Market Report 2026

The oligonucleotide synthesis market size has grown rapidly in recent years. It will grow from $11.92 billion in 2025 to $13.9 billion in 2026 at a compound annual growth rate (CAGR) of 16.6%. The growth in the historic period can be attributed to high cost of synthesis equipment, limited availability of custom oligos, dependency on manual synthesis processes, low awareness among researchers, lengthy production timelines.

The oligonucleotide synthesis market size is expected to see rapid growth in the next few years. It will grow to $26.08 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to growing demand from therapeutic and diagnostic applications, increasing adoption of automated synthesis platforms, advancements in gene therapy research, rising investment in biotechnology research, expansion of oligo-based research and diagnostics globally. Major trends in the forecast period include advancements in gene editing and personalized medicine, integration of cloud-based data management platforms, application of ai for sequence optimization and design, automation in oligonucleotide synthesis processes, iot-enabled equipment monitoring and process tracking.

The increasing prevalence of chronic diseases is expected to drive the growth of the oligonucleotide synthesis market in the coming years. Chronic diseases are conditions that persist for one year or more and require ongoing medical care, often progressing or worsening over time. Oligonucleotides influence gene expression through multiple mechanisms involved in chronic disease pathways. They are capable of targeting mRNA, pre-mRNA, or non-coding RNA to regulate splicing processes, promote degradation, or disrupt protein translation. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050 more than 35 million new cancer cases would occur worldwide, reflecting a 77% increase compared with the estimated 20 million cases reported in 2022. As a result, the growing prevalence of chronic and rare diseases is contributing to the expansion of the oligonucleotide synthesis market.

Key companies operating in the oligonucleotide synthesis market are emphasizing the development of advanced DNA products to improve sequence accuracy, streamline research workflows, and support sophisticated scientific applications. For instance, in July 2024, Ansa Biotechnologies, Inc., a US-based company specializing in complex DNA manufacturing, introduced Ansa Clonal DNA and Ansa DNA Fragments. Ansa Clonal DNA delivers clonal, sequence-perfect DNA of up to 600 base pairs, removing the need for assembly and providing exceptional accuracy for complex synthetic biology projects. This solution offers researchers error-free, ready-to-use DNA sequences. Ansa DNA Fragments consist of sequence-verified linear double-stranded DNA fragments, also up to 600 base pairs, designed to support a wide range of research needs. Using its proprietary enzymatic synthesis process, Ansa produces complex DNA constructs, including repetitive sequences and secondary structures, with a high level of precision.

In June 2024, GSK plc, a UK-based pharmaceutical company, acquired Elsie Biotechnologies for $50 million. This acquisition enables GSK to fully incorporate Elsie’s oligonucleotide discovery, synthesis, and delivery technologies into its research and development operations. The integration is expected to strengthen GSK’s capabilities in advancing oligonucleotide-based therapeutics. Elsie Biotechnologies is a US-based company focused on the development of oligonucleotide medicines.

Major companies operating in the oligonucleotide synthesis market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE HealthCare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Nitto Denko Avecia Inc., Alnylam Pharmaceuticals Inc., Maravai Life Sciences, LGC Limited, Ionis Pharmaceuticals Inc., GenScript Inc., Ajinomoto Bio-Pharma Services, Sarepta Therapeutics Inc., Integrated DNA Technologies Inc., Twist Bioscience Corporation, Eurogentec SA, Kaneka Eurogentec S.A., Biocomma Limited, Bio-Synthesis Inc., TriLink BioTechnologies Incorporated, Generi Biotech s.r.o., ATDBio Ltd., BioAutomation Corporation, Biolegio B.V., Dharmacon Research Inc.

North America was the largest region in the oligonucleotide synthesis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oligonucleotide synthesis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oligonucleotide synthesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oligonucleotide synthesis market by increasing import costs for specialized synthesis reagents, equipment, and automation tools, affecting research institutions, pharmaceutical companies, and diagnostic labs particularly in north america, europe, and asia-pacific. While this can raise operational costs, it also encourages local manufacturing, investment in domestic production, and development of cost-optimized, high-quality oligonucleotide solutions.

The oligonucleotide synthesis market research report is one of a series of new reports that provides oligonucleotide synthesis market statistics, including oligonucleotide synthesis industry global market size, regional shares, competitors with a oligonucleotide synthesis market share, detailed oligonucleotide synthesis market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide synthesis industry. This oligonucleotide synthesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oligonucleotide synthesis is the chemical process of linking nucleotides together to precisely create a product with a specific sequence. This process is widely used in modern laboratory practices, as it provides fast and cost-effective access to custom-made oligonucleotides with the required sequences.

The main types of oligonucleotide synthesis include custom oligos and predesigned oligos. Custom oligos are oligonucleotides produced through solid-phase chemical synthesis, in which the four nucleic acids A, T, C, and G are sequentially added to build a nucleotide chain. Various product types are involved, including oligonucleotides, reagents, equipment, services, purification, and modification, which are utilized across multiple applications such as therapeutic, research, and diagnostic applications.

The oligonucleotide synthesis market consists of revenues earned by entities by providing non-coding RNA inhibition, splicing modulation, gene activation, and programmed gene editing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oligonucleotide synthesis market also includes sales of RNAi oligonucleotides, antisense oligonucleotides, condensation activators, sulfur-transfer reagents, and deprotection reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.